Fredun Pharmaceuticals Limited (FREDUN) fundamentals
Fredun Pharmaceuticals Limited is a listed company, part of the Pharmaceuticals sector, listed on the NSE as FREDUN (ISIN INE194R01017). This page carries its reported financials, balance sheet, cash flow, shareholding pattern and valuation ratios.
What Fredun Pharmaceuticals Limited does
Fredun Pharmaceuticals Ltd. is an India-based pharmaceuticals formulation manufacturing company. The Company is engaged in manufacturing dietary/herbal supplements, nutraceuticals, and other healthcare products, along with animal healthcare products. Its segment includes Fredun Generics, Pet Care, Nutraceuticals, Cosmeceuticals and Mobility. Its Generics Division, marketed under the Fredun Gx brand. The Pet Healthcare segment operates under the Freossi brand. The Nutraceutical Division under Fredun Nutrition brand. Its Cosmeceuticals Division, operating under the Bird N Beauty (BNB) and Beautyfred brands, is focused on skincare and personal care products. Its Mobility Division, operating under Chuu Balm, BraceOn, NebOn, and DigiOn, caters to the ortho rehabilitation aids and pain management market. It offers a range of products, including antihypertensive, antidiabetic, antiretroviral drugs (ARVs) and narcotics. It also provides comprehensive pet care technology platforms.
Valuation and market data
| Last close | ₹1409.70 |
|---|---|
| Market capitalisation | ₹688 crore |
| Enterprise value | ₹690 crore |
| P/E (TTM) | 21.10 |
| Price to book | 2.48 |
| Price to sales (TTM) | 0.59 |
| Book value per share | ₹569.55 |
| Dividend yield | 9.93% |
| Sector | Pharmaceuticals |
| Industry | — |
| Listed since | Mon Aug 17 |
Annual results
| Period | Revenue | Profit before tax | Net profit | EPS |
|---|---|---|---|---|
| Mar 2026 | ₹639 crore | ₹47 crore | ₹33 crore | 66.81 |
| Mar 2025 | ₹456 crore | ₹27 crore | ₹20 crore | 41.78 |
Figures are as reported (consolidated), in ₹ crore.
Shareholding pattern
As of Jul 2026:
| Promoters | 44.6% |
|---|---|
| Foreign institutions (FII) | 1.1% |
| Mutual funds | 0.0% |
| Other domestic institutions | 2.9% |
| Retail and others | 51.4% |
More on BreakPoint
FundaX company research covers every listed company with reported financials. BreakPoint Pro adds the BreakPoint iQ score, the screener and the multibagger board.
Data is sourced from exchange filings and vendor feeds and is for research, not investment advice. Figures can be restated by the company after publication.